Sep 12, 2022 / 12:45PM GMT
Andrew Christopher Ranieri - Morgan Stanley, Research Division - Equity Analyst
Welcome, everyone, to day one of the Morgan Stanley Healthcare Conference. I'm Drew Ranieri, one of the medical device analysts here. It's my pleasure to have Chris Simon, President and CEO of Haemonetics. -- with us here today. Great to see everybody three-dimensionally. Also before we jump in, just a quick disclaimer, but for important disclosures, please see the Morgan Stanley research disclosure website at morganstanley.com research disclosures and if you have any questions, reach out to your sales rep. Chris, thanks for being here today. Great that you're taking the time. And maybe just to first start and you did have some news this morning, but -- and I'd like to get to that. But maybe let's hit on the plasma business first. And really, since the May Analyst Day, you've been discussing the plasma collection volumes are really gaining momentum and you're now seeing recovery across all plasma centres. Can you maybe just talk about what's driving the improvement? Is it an industry level, company level? And maybe just help us
Haemonetics Corp at Morgan Stanley Global Healthcare Conference Transcript
Feb 10, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers